Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(1.79)
# 3,161
Out of 4,931 analysts
49
Total ratings
29.73%
Success rate
-5.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $31.63 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $47.25 | +103.17% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $7.71 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $61.63 | - | 2 | Jun 10, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $27.70 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $6.34 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.25 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $10.16 | +28.05% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $2.60 | - | 2 | Mar 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $55.53 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $77.42 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $37.01 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.61 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.86 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $128.53 | +127.18% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $376.15 | -1.63% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.48 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.51 | - | 1 | May 30, 2017 |
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.63
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $47.25
Upside: +103.17%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $7.71
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $61.63
Upside: -
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $27.70
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.34
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.25
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $10.16
Upside: +28.05%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.60
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $55.53
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $77.42
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $37.01
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.86
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $128.53
Upside: +127.18%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $376.15
Upside: -1.63%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.48
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.51
Upside: -